Evidence map›Paper›PMID 38578902›Full record

ReviewJournal of Parkinson's disease2024

Twelve Years of Drug Prioritization to Help Accelerate Disease Modification Trials in Parkinson's Disease: The International Linked Clinical Trials Initiative.

Richard K Wyse, Tom Isaacs, Roger A Barker, Mark R Cookson, Ted M Dawson, David Devos, David T Dexter, Joy Duffen, Howard Federoff, Brian Fiske and 17 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of Parkinson's disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Ageing, Neurodegeneration and the Endocannabinoid System.Current topics in behavioral neurosciences · 2026
    Review
  5. Treatment Selection and Prioritization for the EJS ACT-PD MAMS Trial Platform.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Richard K WyseCure Parkinson's, London, UK.
Tom IsaacsCure Parkinson's, London, UK.
Roger A BarkerDepartment of Clinical Neurosciences, University of Cambridge, Cambridge, UK.
Mark R CooksonCell Biology and Gene Expression Section, National Institute on Aging, National Institutes of Health, Bethesda, MD, USA.
Ted M DawsonNeuroregeneration and Stem Cell Programs, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
David DevosDepartment of Medical Pharmacology and Neurology, University of Lille, CHU Lille, Lille Neurosciences and Cognition Inserm UMR-S-U1172, Lille, France.
David T DexterParkinson's UK, London, UK.
Joy DuffenCure Parkinson's, London, UK.
Howard FederoffHenry and Susan Samueli College of Health Sciences, University of California, Irvine CA, USA.
Brian FiskeResearch Programs, The Michael J. Fox Foundation for Parkinson's Research, New York, NY, USA.
Thomas FoltynieDepartment of Clinical and Movement Neurosciences, UCL Institute of Neurology, National Hospital for Neurology and Neurosurgery, London, UK.
Susan FoxEdmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, University Health Network, Division of Neurology, University of Toronto, Toronto, ON, Canada.
J Timothy GreenamyreDepartment of Neurology, Pittsburgh Institute for Neurodegenerative Diseases, University of Pittsburgh, Pittsburgh, PA, USA.
Karl KieburtzDepartment of Neurology Center for Health and Technology, University of Rochester, Rochester, NY, USA.
Jeffrey H KordowerASU-Banner Neurodegenerative Disease Research Center and School of Life Sciences, Arizona State University, Tempe, AZ, USA.
Dimitri KraincDepartment of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Helen MatthewsCure Parkinson's, London, UK.
Darren J MooreVan Andel Institute, Grand Rapids, MI, USA.
Leah MursaleenCure Parkinson's, London, UK.
Michael A SchwarzschildDepartment of Neurology, Massachusetts General Hospital, Boston, MA, USA.
Simon R W StottCure Parkinson's, London, UK.
David SulzerDepartment of Neurology, Columbia University, New York, NY, USA.
Per SvenningssonKarolinska Institute, Stockholm, Sweden.
Caroline M TannerDepartment of Neurology, Weill Institute for Neurosciences, University of California San Francisco, San Francisco, CA, USA.
Camille CarrollTranslational and Clinical Research Institute, Newcastle University, Newcastle, UK.
David K SimonBeth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, USA.
Patrik BrundinNeuroscience and Rare Diseases, Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche, Basel, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In 2011, the UK medical research charity Cure Parkinson's set up the international Linked Clinical Trials (iLCT) committee to help expedite the clinical testing of potentially disease modifying therapies for Parkinson's disease (PD). The first committee meeting was held at the Van Andel Institute in Grand Rapids, Michigan in 2012. This group of PD experts has subsequently met annually to assess and prioritize agents that may slow the progression of this neurodegenerative condition, using a systematic approach based on preclinical, epidemiological and, where possible, clinical data. Over the last 12 years, 171 unique agents have been evaluated by the iLCT committee, and there have been 21 completed clinical studies and 20 ongoing trials associated with the initiative. In this review, we briefly outline the iLCT process as well as the clinical development and outcomes of some of the top prioritized agents. We also discuss a few of the lessons that have been learnt, and we conclude with a perspective on what the next decade may bring, including the introduction of multi-arm, multi-stage clinical trial platforms and the possibility of combination therapies for PD.

Indexed as

Clinical Trials as TopicParkinson DiseaseAntiparkinson AgentsHumansAntiparkinson AgentsClinical trialsdisease modificationdrug repurposingneuroprotectionParkinson’s disease

Identifiers

PMID38578902
PMCPMC11191436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.